Research highlights in nmCRPC: PROSPER and SPARTAN studies

Research highlights in nmCRPC: PROSPER and SPARTAN studies

VJOncology

1 year
461 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-resistant prostate cancer. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Armstrong points to limitations with current therapy, and how research into osteomimicry can help develop treatments that aim to cure bone metastases in these patients, rather than merely delaying the symptoms.
Up Next Autoplay